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General Methods
Mass spectra were recorded on a Waters MICROMASS ® LCT PREMIER TM . For HPLC separations, a Cosmosil 5C 18 -AR-II analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1.0 mL/min), a
Cosmosil 5C 18 -AR-II semi-preparative column (Nacalai Tesque, 10 × 250 mm, flow rate 3.0 mL/min) or a Cosmosil 5C 18 -AR-II preparative column (Nacalai Tesque, 20 × 250 mm, flow rate 10 mL/min) was employed, and eluting products were detected by UV at 220 nm. A solvent system consisting of 0.1% TFA aqueous solution (v/v, solvent A) and 0.1% TFA in MeCN (v/v, solvent B) was used for HPLC elution.
Preparation of Peptides 1 and 3
H-AKLRFGCPSRHWKFL-NH 2 H-AKLRFGAPSRHWKFL-NH 2
3
General procedure: Protected peptide resin corresponding to peptide 1 or 3 was prepared by Fmoc Because the resulting thioester 10 was eluted as a single peak on HPLC analysis, risk of epimerization during the converting step could not be verified by the use of peptide 5a and alternative peptide therefore was synthesized. Scheme S3. Conversion of DTDE ester peptide 9 to methylphenyl thioester peptide 10.
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Examination of Epimerization During the Conversion of a SRHW-tagged Parent Peptide to the Corresponding DTDE and Methylthiophenyl Esters
As mentioned above, the parent peptide 5a was unsuitable for the validation of epimerization, alternative parent peptide, Ac-LYRASRHWKFL-NH 2 S28, was synthesized in a manner similar to those employed for 5a.
Preparation of Peptide S28
Ac-LYRASRHWKFL-NH 2
S28
Protected peptide resin corresponding to S28 was constructed on NovaSyn ® TGR resin ( 
Preparation of Stereo
2-Chlorotrityl resin 50 mg (1.57 mmol/g) was swollen in DMF for 30 min. To the resin were added dithiodiethanol (0.1 mL, 10 equiv. for resin) and pyridine (0.07 mL, 10 equiv. for resin) in DMF.
Then, incorporation of the C-terminal AA was performed using Fmoc-L-Ala-OH (or 
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Preparation of Stereo-defined Ligated Products S33 (L-Ala) and S34 (D-Ala)
In order to determine the configuration of alanine of S31 and S32, resulting methylthiophenyl ester S31 and S32 were subjected to NCL with N-terminal cysteinyl peptide, H-CYRANK-NH 2 S35, and then, resulting ligated peptides were analyzed by HPLC using stereo-defined Ac-LYR-L-Ala-CYRANK-NH 2 S33 and Ac-LYR-D-Ala-CYRANK-NH 2 S34 as authentic samples. 
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Preparation of N-terminal Cysteinyl Peptide S35
H-CYRANK-NH 2
S35
Protected peptide resin corresponding to S35 was constructed Methylphenyl thioester peptide S31 (L-Ala) or S32 (D-Ala) (0.08 mg, 0.1 mol) and N-terminal cysteinyl peptide S35 (0.14 mg, 0.13 mol) were dissolved in 6 M Gn·HCl-0.2 M Na phosphate buffer containing 20 mM TCEP and 50 mM sodium ascorbate (pH 7.0, 0.1 mL) to perform NCL reaction. One hour reaction at 37 °C followed by HPLC purifications gave ligated peptides. Analysis of each obtained peptide by HPLC using authentic stereo-defined samples S33 (L-Ala) and S34
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(D-Ala) showed that thioester peptides S31 and S32 had C-terminal L-Ala and D-Ala residues, respectively.
Conversion of Peptides 5 to Peptide Hydrazides 11
General procedure: Peptide 5 (0.20 mg, 0.1 mol) was dissolved in 0.2 M HEPES buffer containing 10 mM NiCl 2 ·6H 2 O and 50% (v/v) MeOH (pH 8.2, 0.1 mL, 1.0 mM peptide). The reaction mixture was incubated at 37 °C for 24 h, followed by addition of NH 2 NH 2 ·H 2 O (4.9 L) into the reaction mixture (final concentration: 5% (v/v) NH 2 NH 2 ). And then, additional reaction at 25 °C for 3 h gave 
Folding for Preparation of ANP 15
Reduced form ANP 27 (0.78 mg, 0.21 mol) was dissolved in 0.1 M Na phosphate buffer containing 6 M Gn·HCl, (pH 7.3, 0.63 mL) and DMSO (0.07 mL). The reaction mixture was incubated at 37 °C for 24 h. The crude material was purified by semi-preparative HPLC to give the purified folded ANP 15 (0.67 mg, 0.18 mol, 86%). 
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temperature for 2 h) followed by HPLC purification afforded the desired peptide. 
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Application of SQAT System to Expressed Protein
HexB S37 (0.057 mg, 0.01 mol) was dissolved in 0.2 M HEPES buffer containing 6 M Gn·HCl, 10 mM NiCl 2 ·6H 2 O and 30% (v/v) MeOH (pH 8.2, 0.1 mL, 0.01 mM protein). The reaction mixture was incubated at 37 °C for 24 h, followed by addition of NH 2 NH 2 ·H 2 O (5.3 L) into the reaction mixture (final concentration: 5% (v/v) NH 2 NH 2 ). And then, the reaction mixture was incubated at 25 °C for 3 h. The protein was then buffer-exchanged, by use of a centrifugal filter equipped with a 10 kDa molecular weight cut off, into 0.2 M Na phosphate buffer containing 6 M Gn·HCl, (pH 3.0, 0.4 mL) by repeated dilution/concentration and ultimately obtained in the original reaction volume of ligation buffer (0.1 mL). The reaction mixture was stored at -10 °C. Then. 10 L of 0.2 M NaNO 2 aq. was added, and the reaction mixture was stored at -10 °C for 1 h. After that, 0.2 M Na phosphate buffer containing 6 M Gn·HCl and 0.2 M MPAA (0.1 mL) was added, and pH of the mixed solution was adjusted to pH 7.0 with 2.0 M NaOH aq. followed by addition of peptide S36 (0.12 mg, 0.1 mol). The reaction mixture was stored at room temperature for 12 h, followed by addition of 30 mM TCEP aq. (pH 7.0, 0.2 mL). And then, the reaction mixture was exchanged into 0.1% TFA aqueous solution by use of a centrifugal filter equipped with a 10 kDa molecular weight cut off followed by silver staining and streptavidin-HRP blotting.
Scheme S10. Application of SQAT system to expressed protein. 
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